Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study

Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study

Abstract Background This study aimed to investigate the safety of sorafenib for the treatment of unresectable hepatocellular carcinoma in Chinese patients. Methods A subgroup of 345 Chinese patients from the international database of the Global Investigation of therapeutic DEcisions in hepatocellula...

Full description

Bibliographic Details
Main Authors: Sheng-Long Ye, Jiamei Yang, Ping Bie, Shuijun Zhang, Xiaoping Chen, Fengyong Liu, Luming Liu, Jie Zhou, Kefeng Dou, Chunyi Hao, Guoliang Shao, Qiang Xia, Yajin Chen, Jijin Yang, Xiaxing Deng, Yunpeng Liu, Yunfei Yuan, Zhiren Fu, Keiko Nakajima, Zhengguang Lv
Format: Article
Language:English
Published: BMC 2018-03-01
Series:BMC Cancer
Online Access:http://link.springer.com/article/10.1186/s12885-018-4144-9

Internet

http://link.springer.com/article/10.1186/s12885-018-4144-9

Similar Items